Natera (NASDAQ:NTRA) Insider Sells $243,656.89 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,013 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total value of $243,656.89. Following the completion of the transaction, the insider directly owned 143,686 shares of the company’s stock, valued at approximately $34,560,793.58. This trade represents a 0.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total value of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.

Natera Trading Down 1.9%

NTRA traded down $4.45 on Thursday, hitting $231.48. 947,123 shares of the company were exchanged, compared to its average volume of 1,043,018. The firm has a 50-day moving average price of $235.90 and a two-hundred day moving average price of $193.29. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The company has a market cap of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the firm posted ($0.26) EPS. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Guggenheim upped their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. JPMorgan Chase & Co. raised their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. UBS Group upped their price objective on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price target for the company in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Institutional Investors Weigh In On Natera

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares during the period. State Street Corp grew its holdings in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares during the period. Franklin Resources Inc. increased its stake in Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.